Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published August 2016
  • Article
  • Info & Metrics
  • PDF
Loading

Improved Mithramycin Analogues

Osgood et al. Page 4105

The clinical suppression of the EWS-FLI1 transcription factor has not been achieved despite a known dependence of Ewing sarcoma on this target. Osgood and colleagues previously demonstrated that the DNA-binding compound mithramycin blocks the activity of the EWS-FLI1 transcription factor to suppress tumor growth in preclinical models. Unfortunately, the clinical translation of this compound as an EWS-FLI1–directed therapy was limited by toxicity. In this study, the authors optimized the structure of mithramycin and identified two second-generation analogues that maintain suppression of EWS-FLI1 but have improved toxicity profiles.

Quizartinib for Children with Relapsed Leukemia

Cooper et al. Page 4014

Clinical testing of FLT3 inhibitors in children with relapsed leukemia has been limited by off-target toxicity and an inability to achieve sustained inhibition. Cooper and colleagues report the results of a phase I clinical trial using the second-generation FLT3 inhibitor, quizartinib, combined with chemotherapy for relapsed pediatric leukemia. The authors demonstrate that quizartinib is well tolerated, provides sustained inhibition of FLT3 phosphorylation, and shows promising therapeutic activity in children with FLT3 mutations.

Hypoxia Classifier in Cervical Cancer

Fjeldbo et al. Page 4067

Modification of tumor hypoxia may improve radiotherapy for cervical cancer; however, methods for classifying patients according to hypoxia are required for evaluation of adjuvant hypoxia-modifying drugs. Fjeldbo and colleagues combined DCE-MRI and gene-expression profiles of cervical cancer patients to construct an image-associated, hypoxia gene classifier for stratifying hypoxic tumors. The robustness of the classifier was demonstrated by successful validation of its hypoxia association and prognostic value across cohorts and assay platforms. The classifier shows promise as a genomic tool to aid treatment decision making both alone and for future integration with DCE-MRI.

HDAC Inhibitors Augment PD-1 Immunotherapy

Zheng et al. Page 4119

Zheng and colleagues report that histone deacetylase (HDAC) inhibitors increase the expression of multiple T-cell chemokines in cancer cells, macrophages, and T cells. In vivo, the HDAC inhibitor romidepsin increased chemokine expression and enhanced T-cell infiltration and T-cell–dependent tumor regression. Furthermore, romidepsin enhanced responses to PD-1 blockade immunotherapy in lung cancer. These results suggest that HDAC inhibitors can be used to increase T-cell infiltration into tumors and, in combination with PD-1 blockade, can enhance immunotherapy.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 22 (16)
August 2016
Volume 22, Issue 16
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Clin Cancer Res August 15 2016 (22) (16) 3985;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Clin Cancer Res August 15 2016 (22) (16) 3985;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Improved Mithramycin Analogues
    • Quizartinib for Children with Relapsed Leukemia
    • Hypoxia Classifier in Cervical Cancer
    • HDAC Inhibitors Augment PD-1 Immunotherapy
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement